In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

The firm will launch a Phase I trial in healthy volunteers in the Netherlands to establish safety and proof-of-target engagement.

In this tough-to-treat cancer type, more patients receiving anzu-cel saw their tumors shrink and had durable responses than what's been seen with other therapies.

The Sweden-based Phase II trial will evaluate how well the company's gallium-68-labeled PET tracer identifies best responders to Enhertu.

NEW YORK – Galapagos on Tuesday said that after a strategic review it has decided to wind down its cell therapy business, which includes several CAR T-cell therapies in development for blood cancers ...

While Natera said it will seek FDA approval for Signatera based on data from IMvigor011, the readout from another ctDNA-guided de-escalation study was more nuanced.